Synlogic, Inc.

NASDAQ:SYBX

1.4 (USD) • At close September 13, 2024
Bedrijfsnaam Synlogic, Inc.
Symbool SYBX
Munteenheid USD
Prijs 1.4
Beurswaarde 16,374,540
Dividendpercentage 0%
52-weken bereik 0.234 - 5.708
Industrie Biotechnology
Sector Healthcare
CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Website https://www.synlogictx.com

An error occurred while fetching data.

Over Synlogic, Inc.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat

Vergelijkbare Aandelen

Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd.

ENLV

1.57 USD

Homology Medicines, Inc. logo

Homology Medicines, Inc.

FIXX

0.935 USD

Eliem Therapeutics, Inc. logo

Eliem Therapeutics, Inc.

ELYM

8.46 USD

Clearside Biomedical, Inc. logo

Clearside Biomedical, Inc.

CLSD

1.23 USD

LENSAR, Inc. logo

LENSAR, Inc.

LNSR

5.06 USD

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

EFTR

0.04 USD

Longboard Pharmaceuticals, Inc. logo

Longboard Pharmaceuticals, Inc.

LBPH

34.32 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)